Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
2.225
-0.075 (-3.26%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Artiva Biotherapeutics Revenue
In the year 2024, Artiva Biotherapeutics had annual revenue of $251.00K, down -99.25%.
Revenue (ttm)
$251.00K
Revenue Growth
-99.25%
P/S Ratio
100.48
Revenue / Employee
$2,820
Employees
89
Market Cap
54.57M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ARTV News
- 12 days ago - Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - GlobeNewsWire
- 20 days ago - Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 27 days ago - Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 5 months ago - Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewsWire
- 6 months ago - Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - GlobeNewsWire